{
  "relevance_rule": {
    "rule_text": "All abstracts that have client provided keywords",
    "approach": "keywords",
    "key_concepts": {
      "keywords": [
        "Hyperphosphatemia",
        "Parathyroid hormone",
        "Calcitriol",
        "Chronic kidney disease",
        "ESRD",
        "Phosphate binder",
        "Sevelamer",
        "sucroferric oxyhydroxide",
        "lanthanum carbonate",
        "Ferric citrate",
        "Calcium acetate",
        "Constipation",
        "Tenapanor",
        "Claudins",
        "FGF receptor",
        "Albuminuria",
        "nicotinamide",
        "vitamin D",
        "SGLT2 inhibitors",
        "canagliflozin",
        "Dapagliflozin",
        "Empagliflozin",
        "Ozempic",
        "Calcium carbonate",
        "Serum phosphate",
        "Phosphate",
        "Fibroblast growth factor 23",
        "Hemodialysis",
        "Dialysis",
        "Dialysis Outcomes and Practice Patterns Study",
        "Sodium hydrogen transport exchanger 3",
        "sodium-dependent phosphate cotransporter 2b",
        "KDIGO",
        "KDOQI",
        "Sodium",
        "Phosphorus",
        "Klotho",
        "Tight junctions",
        "Occludins",
        "Vascular calcification",
        "Bristol Stool Form Scale",
        "Interdialytic weight gain",
        "peritoneal dialysis",
        "NTX1942",
        "SLC34A2",
        "Glomerular",
        "CKD-MBD",
        "Smooth muscle calcification",
        "Oxylanthanum carbonate"
      ],
      "categories": [],
      "contextual_concepts": []
    },
    "reasoning": "This rule explicitly states that relevance is determined by the presence of client provided keywords."
  },
  "priority_rules": [
    {
      "priority": "High",
      "rule_text": "Phase 2 data, Phase 3 data (including meta-analyses), real-world data (including PROs and registry data), Phosphate binders/phosphate lowering treatment; EXCLUDE Ardelyx sponsored abstracts",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "Phase 2",
          "Phase 3",
          "meta-analysis",
          "real-world data",
          "PRO",
          "patient reported outcomes",
          "registry data",
          "Phosphate binder",
          "phosphate lowering treatment"
        ],
        "categories": [
          "Clinical trial phase",
          "Data type",
          "Treatment type"
        ],
        "contextual_concepts": [
          "Meta-analyses",
          "Real-world evidence",
          "Patient reported outcomes",
          "Registry studies"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored"
      ],
      "reasoning": "This rule requires both keyword matching (trial phases, treatments) and context (meta-analyses, real-world data, PROs). Ardelyx sponsored abstracts are excluded to ensure mutual exclusivity with the Internal priority."
    },
    {
      "priority": "Internal",
      "rule_text": "Ardelyx sponsored abstracts",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Ardelyx sponsored"
        ],
        "categories": [
          "Sponsor"
        ],
        "contextual_concepts": []
      },
      "exclusions": [],
      "reasoning": "This rule is based on the presence of the sponsor name and is mutually exclusive from other priorities."
    },
    {
      "priority": "Medium",
      "rule_text": "Phase 1 data, retrospective analyses, prognostic studies, trial designs, preclinical studies; studies with trial outcomes and endpoints; other general studies; EXCLUDE Ardelyx sponsored abstracts and any abstracts qualifying for High priority",
      "approach": "hybrid",
      "key_concepts": {
        "keywords": [
          "Phase 1",
          "retrospective analysis",
          "prognostic study",
          "trial design",
          "preclinical study",
          "outcomes",
          "endpoints"
        ],
        "categories": [
          "Clinical trial phase",
          "Study type"
        ],
        "contextual_concepts": [
          "General studies",
          "Trial outcomes",
          "Endpoints"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored",
        "Phase 2",
        "Phase 3",
        "meta-analysis",
        "real-world data",
        "PRO",
        "patient reported outcomes",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment"
      ],
      "reasoning": "This rule covers studies not qualifying for High or Internal priority, and requires both keyword and context matching. Exclusions ensure mutual exclusivity."
    },
    {
      "priority": "Low",
      "rule_text": "All abstracts that only have mention of an indication and does not include any other data; EXCLUDE Ardelyx sponsored abstracts and any abstracts qualifying for High or Medium priority",
      "approach": "context",
      "key_concepts": {
        "keywords": [],
        "categories": [
          "Indication only"
        ],
        "contextual_concepts": [
          "Mention of indication without data"
        ]
      },
      "exclusions": [
        "Ardelyx sponsored",
        "Phase 2",
        "Phase 3",
        "meta-analysis",
        "real-world data",
        "PRO",
        "patient reported outcomes",
        "registry data",
        "Phosphate binder",
        "phosphate lowering treatment",
        "Phase 1",
        "retrospective analysis",
        "prognostic study",
        "trial design",
        "preclinical study",
        "outcomes",
        "endpoints"
      ],
      "reasoning": "This rule requires semantic/contextual understanding to identify abstracts that only mention an indication without any data, and excludes all higher priority categories for mutual exclusivity."
    }
  ]
}